Skip to main content
S 1813 117th Congress Senate Health Drug safety, medical device, and laboratory regulation Drug therapy Government information and archives Health care coverage and access Health programs administration and funding Health promotion and preventive care Higher education Medical research Medical tests and diagnostic methods Neurological disorders Prescription drugs Public-private cooperation Research administration and funding Research and development Social work, volunteer service, charitable organizations

Accelerating Access to Critical Therapies for ALS Act

Introduced: October 28, 2021 Introduced by: Coons, Christopher A. Democratic · Delaware See on congress.gov
This bill died when the 117th Congress ended
It never became law before the 117th Congress (2021–2022) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
May 25, 2021
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
May 25, 2021
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Accelerating Access to Critical Therapies for ALS Act

This bill establishes grant programs to address neurodegenerative diseases, such as amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease), and contains other related provisions.

The Department of Health and Human Services (HHS) shall award grants to eligible entities to facilitate patients' access to investigational drugs that diagnose or treat ALS. The Food and Drug Administration (FDA) shall award grants to public and private entities to cover the costs of research and development of drugs that diagnose or treat ALS and other severely debilitating neurodegenerative diseases.

HHS shall also establish the Public-Private Partnership for Neurodegenerative Diseases between the National Institutes of Health, the FDA, and at least one eligible entity (generally, an institution of higher education or a nonprofit organization). The partnership shall support the development and regulatory review of drugs that address ALS and other rare neurodegenerative diseases.

The FDA shall publish on its website a five-year action plan for fostering the development of drugs that improve or extend the lives of people living with rare neurodegenerative diseases.

What's happening now May 25, 2021

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

 Related & companion bills 1
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Cosponsors 50
D
Warner, Mark R.
Virginia · Dec 16, 2021
D
Booker, Cory A.
New Jersey · Dec 15, 2021
R
Blackburn, Marsha
Tennessee · Dec 14, 2021
D
Reed, Jack
Rhode Island · Dec 14, 2021
R
Hagerty, Bill
Tennessee · Dec 13, 2021
R
Kennedy, John
Louisiana · Dec 9, 2021
D
Ossoff, Jon
Georgia · Dec 9, 2021
R
Daines, Steve
Montana · Dec 8, 2021
R
Rounds, Mike
South Dakota · Dec 6, 2021
I
Sanders, Bernard
Vermont · Dec 6, 2021
R
Fischer, Deb
Nebraska · Dec 2, 2021
D
Heinrich, Martin
New Mexico · Dec 2, 2021
D
Duckworth, Tammy
Illinois · Nov 29, 2021
D
Merkley, Jeff
Oregon · Nov 19, 2021
R
Barrasso, John
Wyoming · Nov 18, 2021
R
Lummis, Cynthia M.
Wyoming · Nov 18, 2021
R
Cassidy, Bill
Louisiana · Nov 17, 2021
D
Baldwin, Tammy
Wisconsin · Nov 15, 2021
D
Whitehouse, Sheldon
Rhode Island · Nov 15, 2021
Blunt, Roy
· Oct 28, 2021
D
Hirono, Mazie K.
Hawaii · Oct 25, 2021
D
Hassan, Margaret Wood
New Hampshire · Oct 21, 2021
D
Peters, Gary C.
Michigan · Oct 18, 2021
D
Smith, Tina
Minnesota · Oct 18, 2021
D
Cortez Masto, Catherine
Nevada · Oct 7, 2021
D
Van Hollen, Chris
Maryland · Oct 6, 2021
D
Klobuchar, Amy
Minnesota · Oct 4, 2021
R
Sullivan, Dan
Alaska · Oct 4, 2021
D
Durbin, Richard J.
Illinois · Sep 28, 2021
D
Warren, Elizabeth
Massachusetts · Sep 27, 2021
R
Collins, Susan M.
Maine · Sep 23, 2021
R
Thune, John
South Dakota · Sep 23, 2021
D
Markey, Edward J.
Massachusetts · Sep 22, 2021
R
Moran, Jerry
Kansas · Sep 20, 2021
D
Blumenthal, Richard
Connecticut · Sep 13, 2021
D
Gillibrand, Kirsten E.
New York · Sep 13, 2021
D
Murphy, Christopher
Connecticut · Sep 13, 2021
D
Rosen, Jacky
Nevada · Sep 13, 2021
D
Schatz, Brian
Hawaii · Sep 13, 2021
R
Hoeven, John
North Dakota · Aug 9, 2021
R
Marshall, Roger
Kansas · Aug 9, 2021
D
Bennet, Michael F.
Colorado · Jul 28, 2021
D
Kelly, Mark
Arizona · Jul 28, 2021
D
Padilla, Alex
California · Jul 28, 2021
Sinema, Kyrsten
· Jul 28, 2021
R
Capito, Shelley Moore
West Virginia · Jun 10, 2021
D
Shaheen, Jeanne
New Hampshire · Jun 10, 2021
R
Boozman, John
Arkansas · Jun 7, 2021
I
King, Angus S., Jr.
Maine · Jun 7, 2021
R
Murkowski, Lisa
Alaska · May 25, 2021
Cite this page click to expand
APA
U.S. Congress. (2026). S. 1813: Accelerating Access to Critical Therapies for ALS Act. 117th Congress. Open America. https://openamerica.io/bill/117-S-1813/
MLA
"S. 1813: Accelerating Access to Critical Therapies for ALS Act." 117th Congress, 2026, Open America, https://openamerica.io/bill/117-S-1813/.
Bluebook (legal)
S. 1813, 117th Cong. (2026), https://openamerica.io/bill/117-S-1813/.
Markdown link
[S. 1813: Accelerating Access to Critical Therapies for ALS Act](https://openamerica.io/bill/117-S-1813/)
Report a problem